Search

Your search keyword '"Fei, Zhenghua"' showing total 8 results
Start Over Author "Fei, Zhenghua" Publication Year Range Last 3 years
8 results on '"Fei, Zhenghua"'

2. FTX promotes esophageal cancer progression and desensitizes esophageal cancer cells to ionizing radiation by microRNA-99a/b-3p/WEE1/ERCC1 axis.

Author

Xu, Yangjie, Huang, Chaoming, Mao, Zijuan, Fu, Yuanyuan, Hao, Qiongyu, and Fei, Zhenghua

Subjects
CANCER cell growth, EXCISION repair, ESOPHAGEAL cancer, CANCER cell migration, ONCOLOGIC surgery
Abstract

This study was conducted to uncover the underlying cellular and molecular mechanisms of five prime to Xist (FTX) dysregulation in esophageal cancer (EC). The gene expression in tumor tissues was detected using western blot, immunohistochemistry, and quantitative real-time polymerase chain reaction (qPCR). The dual-luciferase reporter and RNA FISH assays confirmed the interaction between miRNA and target genes. Mouse models for Xenograft and lung metastasis were used to assess EC cell tumorigenesis and metastasis. This study finds that up-regulated FTX in patients with esophageal cancer correlates with poor clinical outcomes. Silencing FTX inhibits esophageal cancer cell growth and migration in vitro and tumor metastasis in vivo. miR-99a/b-3p sensitizes esophageal cancer cells to ionizing radiation by WEE1 (Wee1-like protein kinase) and ERCC1 (excision repair cross-complementation group 1) in vitro. FTX promotes the malignant biological phenotype of esophageal cancer cells. Mechanistically, FTX acts as a ceRNA to regulate the transcription of WEE1 and ERCC1 by sponging hsa-miR-99a/b-3p. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Accepting Immunotherapy After Multiline Treatment Failure: An Exploration of the Anxiety and Depression in Patients with Advanced Cancer Experience

Author

Xie,Qingqing, Sun,Caixia, Fei,Zhenghua, and Yang,Xujing

Subjects
Patient Preference and Adherence, quality of life, Health Policy, depression, cancer, Medicine (miscellaneous), immunotherapy, anxiety, Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Social Sciences (miscellaneous), Original Research
Abstract

Qingqing Xie,1 Caixia Sun,2 Zhenghua Fei,1 Xujing Yang1 1Department of Radiation and Medical Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People’s Republic of China; 2Department of Nursing, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People’s Republic of ChinaCorrespondence: Xujing YangDepartment of Radiation and Medical Oncology, The First Affiliated Hospital of Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou, 325000, People’s Republic of ChinaEmail wzyyysj7979@126.comBackground: Tumor immunotherapy is a promising therapeutic strategy for patients with advanced cancers, and some tumors have profound and durable tumor regression. However, immunotherapy is still in the clinical trial stage with elusive long-term effects and complications as a new strategy. It is unclear whether patients possess an accurate understanding of the clinical benefits associated with these agents.Objective: To investigate the anxiety and depression of patients with advanced cancer who received immunotherapy using programmed death-1 or programmed death-ligand 1 after multiline treatment failure, explore the influencing factors, and provide a reference for clinical medical staff and psychological support for patients.Methods: The Hospital Anxiety and Depression Scale was used to calculate the anxiety and depression scores before and after 1, 2, and 3 courses of treatment, respectively. The patients with anxiety and depression were counted. Purposive sampling was used to conduct face-to-face semi-structured interviews with 21 patients to find out the reasons. The obtained data were analyzed and collated using Colaizzi’s phenomenological method.Results: One hundred and twenty-six patients with advanced cancers were included in the study. Before and after 1, 2 and 3 courses of treatment, 18.26%, 23.0%, 50% and 54% of patients suffered from anxiety and depression, respectively. The proportion of patients with anxiety and depression during immunotherapy kept increasing, mainly due to therapeutic efficacy below expectation, lack of timely information after treatment, lack of awareness of treatment and drugs, and lack of family and social support.Conclusion: Patients with advanced tumors after multiline treatment failure are susceptible to anxiety and depression during immunotherapy. It is necessary to test the emotional state of patients in time and carry out early intervention. Nursing staffs and medical staffs should adopt personalized measures to meet the psychological needs of patients.Keywords: anxiety, depression, cancer, immunotherapy, quality of life

Published
2022
Full Text
View/download PDF

6. Clinical Trials of Liposomes in Children’s Anticancer Therapy: A Comprehensive Analysis of Trials Registered on ClinicalTrials.gov

Author

Feng,Zhaosong, Gu,Yuyang, Yuan,Mengping, Xiao,Renzhong, Fei,Zhenghua, Feng,Zhaosong, Gu,Yuyang, Yuan,Mengping, Xiao,Renzhong, and Fei,Zhenghua

Abstract

Zhaosong Feng,1 Yuyang Gu,2 Mengping Yuan,3 Renzhong Xiao,4 Zhenghua Fei2 1Pharmacy Department, Jianhu People’s Hospital, Jianhu, Jiangsu Province, 224700, People’s Republic of China; 2Department of Oncology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, 325000, People’s Republic of China; 3Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, 325000, People’s Republic of China; 4R&D Center, Hunan Royal Pharmaceutical Technology Co., Ltd., Changsha, Hunan Province, 410000, People’s Republic of ChinaCorrespondence: Renzhong Xiao, R&D Center, Hunan Royal Pharmaceutical Technology Co., Ltd., Changsha City, Hunan Province, 410000, People’s Republic of China, Email jimmy841228@163.com Zhenghua Fei, Department of Oncology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, 325000, People’s Republic of China, Email feizhenghua@wzhospital.cnObjective: Clinical trials have become essential for driving the development of medicine. However, little is known about the current status of clinical trials on liposomes in children’s anticancer therapy (LCAT). This study aimed to synthesize current finding from clinical trials of LCAT in ClinicalTrials.gov.Methods: A cross-sectional descriptive study of clinical trials on LCAT was conducted, using studies registered on ClinicalTrials.gov through December 30, 2021.Results: A total of 74 eligible trials were identified, accounting for 4.8% (74/1552) of all trials on liposomes for cancer therapy. Among these trials, 70 (94.6%) were interventional trials, and the remaining 4 (5.4%) were observational trials. Of the 70 interventional trials, 63 (90.0%) were for treatment, 48.6% were involving unlabeled allocations, 30.0% were randomized, 52.9% were single group assignment, 71.4% were without masking, 28.6% were Phase 3 trials, 30.0% were Phase 1 trials, and 24.3% were P

Published
2022

8. [Clinical phenotype and genetic analysis of a child featuring short stature and multiple skeletal dysplasia].

Author

Lyu Y, Qi F, Fei Z, Gao H, and Gu C

Subjects
Humans, Infant, Male, Computational Biology, Mothers, Mutation, Phenotype, Dwarfism genetics, Osteochondrodysplasias genetics, Pectus Carinatum
Abstract

Objective: To analyze the clinical phenotype and genetic basis for a child featuring familial short stature., Methods: A child who was admitted to Huzhou Maternal and Child Health Care Hospital on October 7, 2021 for growth retardation and pectus carinatum was selected as the study subject. Physical exam and medical imaging was performed. The child was subjected to whole exome sequencing, and candidate variants were verified by Sanger sequencing and bioinformatic analysis., Results: The child, a 1-year-old male, had manifested with slightly short stature (Z = -2.03), midfacial dysplasia, and multiple skeletal dysplasia such as pectus carinatum, irregular vertebral morphology, and defect of lumbar anterior bones. His mother, maternal grandmother and great-maternal grandfather also had short stature. WES revealed that the child has harbored a heterozygous c.2858dupA (p.Asp953GlufsTer476) frameshifting variant of the ACAN gene, which was inherited from his mother. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the c.2858dup (p.Sp953Glufster476) variant was classified as likely pathogenic (PVS1+PM2_Supporting). The patient has shown marked improved height after receiving 11 months of treatment with human recombinant growth hormone (supplemental dose) starting from 20 months of age., Conclusion: The ACAN: c.2858dup (p.Asp953GlufsTer476) variant probably underlay the pathogenesis of short stature in this child.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results